August was first-half reporting season for most of the companies we cover. Since the start of the cycle, we have published thirteen coverage updates: twelve on interim results, one on the full year.
The pattern was familiar. Again and again, the headline number said one thing, while the operating business said another. That gap — between what companies disclose and what investors actually understand — is exactly why we started The SEA Analyst.
August in Review
Not every update warranted a standalone email, so this roundup brings the reporting cycle together. Each header links to the full article.
HL Global (AVX), 7 Aug The board said recurring profits have not been sufficient to support dividends, and the market is pricing exactly that.
JustCo (JCO), 10 Aug The SEA organic business is improving, but the reported profit was an accounting gain and the revenue growth came from a consolidation rather than new business.
Jollibee (JFC), 11 Aug Record headline profit, but overseas earnings went backwards, net debt rose ₱12 billion, and the Wall Street re-rating thesis is quieter, not louder. Since publication: Jollibee has confirmed Hong Kong over the US as the venue for its international unit listing.
Foundation Healthcare (FHH), 17 Aug The reported profit was distorted by a pre-IPO swap structure that ended on 1 July, the day after the first-half closed; the number that matters, core margin, moved down.
Sheng Siong (OV8), 20 Aug The 31.8% gross margin confirms the quality thesis, but the S$520 million Sungei Kadut build now governs the stock.
UltraGreen.ai (ULG), 20 Aug Two US approvals have appeared — Zydus in August, Provepharm in July; the moat is real, and how far competition erodes it is the open question.
Haw Par (H02), 21 Aug Strip out last year's anniversary special dividends and the income stream is intact; at S$15.06, the market caps the company below its UOB and UOL stakes alone.
Q&M Dental (QC7), 22 Aug Core dental profit grew 10%, but Q&M is committing close to a third of its market value to a pan-Asian rollup across three markets at once.
Centurion (OU8), 23 Aug Revenue grew 31% and core profit grew 34%; reported EPS fell 64% because of CAREIT minority interests and non-core valuation effects, not the operating business.
HRnetGroup (CHZ), 24 Aug Singapore posted its first gross-profit rise in three years, and management for the first time framed the company around unlocking value for minority shareholders — the language has moved; the action has not.
PropNex (OYY), 26 Aug The thesis held through the launch drought with market share rising in every segment, but profit fell 3.1% on flat revenue and that margin compression is worth watching into the second half.
Hafary Holdings (5VS), 30 Aug Singapore held, but the Kluang plant lost more money on less revenue — the thesis has one more half to show that the miss was timing, not structure.
Tiong Woon (BQM), 1 Sep Revenue and profit both hit records for the full year; the stock still trades at half its book value.
A Coverage Status System
Every company we cover carries a thesis.
But theses age at different rates — some are live and moving, others are valid but waiting, and a few have run their course. Treating all of them the same way would mean updating when there is nothing new to say, and going quiet when something is actually happening.
We are introducing a coverage status for each company in our coverage: Active Coverage, Catalyst Watch, or Stop.
Active Coverage means the thesis is live and we are tracking it. Expect updates when material developments occur.
Catalyst Watch means the thesis is valid but the trigger is indefinite. The company is not a value trap — there is no structural reason the discount never closes — but there is no near-term catalyst and no management action expected. We will not send regular updates on Catalyst Watch names, but we will revisit when the facts move.
Stop means the thesis has closed — either because the discount is structural with no credible path to close, or because the investment case now depends on a factor that is unlikely to materialise.
Going forward, every company in our coverage carries one of these statuses. The full list, all nineteen names with status and rationale, is in our coverage map.
What We Are Working On
Over the next three to six months, three areas are where we will be watching most closely and where most of our new initiations will come from.
Healthcare in Southeast Asia. Ageing populations and rising household incomes across the region are directing more spending toward private providers, and the consolidation wave that followed is visible across multiple markets and multiple layers of the value chain. We cover Foundation Healthcare, Q&M Dental, and Hyphens Pharma — and the sector is wider than these three names suggest.
AI in Southeast Asia. Our OSAT sector survey mapped the chip-testing layer of the AI supply chain. The layers above it, from test equipment to data centres to software, each have their own listed exposure across SEA. Which companies are genuinely part of the stack, and which are merely borrowing the label, is the question we want to answer.
Consumer Staples in Southeast Asia. The question Sheng Siong and Jollibee have sharpened is whether SEA consumer staples ever earn the defensive premium their developed-market equivalents command. The cohort is larger than it first appears: Yeo's brought in a Nestle executive as CEO, Kimly is moving to the SGX Mainboard, and coffee chains like Oriental Kopi and Fore Coffee are already listed with more, more and more preparing to list.
Alongside these, we will continue reviewing IPOs as they come to market across the region. And where we find a company or angle that the market has significantly overlooked, outside of any planned sector, we will write about it.
A Note on Feedback
Several readers have written in with corrections, privately and in the comments, and we value every one of them.
If the direction we are taking — whether it is the depth of analysis, the companies we cover, or the cadence — is not what you were looking for, write to us at research@theseaanalyst.com.
We have also heard kind words. Our OSAT sector survey was reposted by Unisem, one of the companies the survey covered. Prof. Mak of NUS wrote that "the market needs deep analysis like this more than ever as stock exchanges chase more listings" on our All-Link IPO Review. And privately, readers have written in with notes like: "Keep doing good work. Always looking for high quality SEA stock research."
We are grateful for all of it. We also post on LinkedIn. Find us here if you prefer catching the research that way.
Thank you for reading.
The SEA Analyst
The SEA Analyst is an independent research and education publication. It is not licensed or regulated as a financial adviser in any jurisdiction, and nothing we publish is financial advice or a recommendation to buy or sell any security. We do not publish price targets or forecasts of how a security will trade, and we disclose our own position in every piece. Do your own research, and consult a licensed professional before making any investment decision.